Curcumin and piperazin in association with chemotherapy protocol for cutaneous lymphoma: animal clinical report

The anticancer properties of curcumin were associated with its ability to promote apoptosis, decrease metastatic potential, and proliferation inhibition of distinct tumor types. The objective of the present study was to describe an animal clinical case, reporting the combination of curcumin (450mg Curcuma longa L. rhizome extract), and piperine (15mg Piper nigrum fruit extract) associated with chemotherapy for cutaneous lymphoma treatment. The phytotherapeutic treatment was continued every 12 hours, and the chemotherapy protocol was a combination of doxorubicin, cyclophosphamide, vincristine, and prednisone. The patient demonstrated a partial response, identified by more than 50% of tumor diameter regression. However, the lesions relapsed in the sixth week, and the lomustine was used. The partial remission was again achieved, and the 19-week maintenance protocol with metronomic therapy using cyclophosphamide was introduced for ten consecutive months It was observed that these treatments provided quality survival for the cancer patient, demonstrating the benefit of this co-adjuvant therapy for the chemotherapy protocol cancer treatment. However, the total cure could not be achieved for this patient.